Description
Thcell line is adriamycin-resistant cell line has been developed by exposure of the parent L929 murine fibroblast cell line to increasing concentrations of doxorubicin in-vitro. L929/A cells can be used in the development of novel anti-cancer treatments. Resistance can be circumvented by modulating agents such as verapamil and quinine. The parent cell line L929 was derived from normal subcutaneous areolar adipose tissue.
Adherent Suspension
Adherent
Suggested Medium
RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM L-Glutamine + 0.086uM Doxorubicin hydrochloride.
Quality Control
L929/A Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Shippment
L929/A Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
L929/A Cell Line is for research use only
